

 Mission of the AABC

The mission of Alzheimer's Association® Business Consortium (AABC) is to advance Alzheimer's disease research and innovation in small- and medium-size biotechnology, diagnostics, medical device and contract research organizations.

The members of AABC work in areas of common interest pre-competitively to advance both the field of Alzheimer's research and the goals of its member organizations. AABC members provide leadership and direction to the group's areas of focus, which include but are not limited to: collaborations, recognition and visibility, and knowledge and information sharing. To join the membership mailing list please email Charles Stacey (cstacey@acerapharma.com), co-chair; Kira Sheinerman (ksheinerman@diamirbio.com), co-chair; or Jim Hendrix (jhendrix@alz.org), facilitator.

 Welcome New Members

AABC is growing! We welcome these new members:

» **Eyal Baror, M.Sc. – Neuronix**

Neuronix develops new methods for modifying the course of treatment for Alzheimer's disease. [Read more](#).

» **Michael Agadjanyan, Ph.D., D.Sc. – The Institute for Molecular Medicine**

The scientific goal of the Institute for Molecular Medicine is to apply basic and translational molecular research approaches to better understand and eventually treat catastrophic human chronic diseases. [Read more](#).

» **Harry Lander, Ph.D., M.B.A. – Capo Therapeutics**

Capo Therapeutics, Inc. is focused on the generation of peptide or DNA-based epitope vaccines for Alzheimer's disease. [Read more](#).

» **Malcom Ward, Ph.D. – Aulesa Biosciences**

Aulesa Biosciences, a non-profit organization, enables the pursuit of important research objectives associated with healthcare issues of growing public concern. Aulesa's dementia initiative focuses on the detection and characterization of dementia-related protein fragments within peripheral fluids such as CSF and plasma. [Read more](#).

 News from AABC Members and Growth AD Companies

AABC Translational Animal Models Group Update

The AABC Translation Animal Models Group, chaired by Joseph Araujo, Intervivo Solutions, and facilitated by Jim Hendrix, Ph.D., Alzheimer's Association director of Global Science Initiatives, has developed a subgroup of members to plan an Animal Models Symposium that will focus on understanding the history of Alzheimer's disease animal models, explore the current state-of-the-science, identify knowledge gaps and recommend specific actions in order to develop the next generation of Alzheimer's disease animal models. The symposium is tentatively scheduled for 2018. More details are forthcoming.

 Schedule of Events for Q3 and Q4 2017

For those who are not familiar with AABC, we encourage you to get involved by attending one of our events listed below.

AABC Lunch at Clinical Trials on Alzheimer's Disease (CTAD) 2017

Wednesday, Nov. 1, 1-3 p.m. ET
Boston Park Plaza Hotel, Cambridge Room
50 Park Plaza, Boston, MA 02116

Webinar: AABC Ask the Expert

Early December. Date/time TBD
Year-End View - Current Investment Environment in Alzheimer's Disease

Past Events

AABC Ask The Expert

On Sept. 12, Mark Ammann, Pharm.D. and president of Catalyst Regulatory Services, LLC, presented “The Regulatory Environment for Alzheimer’s Therapeutics and Diagnostics.” Slides from the webinar are available on the [AABC webpage](#).

AABC/ISTAART Joint Webinar

On Oct. 19, AABC and the Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART) hosted a joint webinar titled “Biotech Innovation in New Therapeutic Approaches to Alzheimer’s Disease.” The webinar highlighted three AABC member companies: Accera, T3D Therapeutics and Tetra Discovery.

» AAIC 2017 Review

The Alzheimer’s Association International Conference® 2017 (AAIC®) was the largest in the event’s history, with more than 5,600 participants from over 60 countries. The conference, described by attendees as the best AAIC scientific program to date, highlighted significant advancements in the field, including:

- » Randall Bateman, M.D., Washington University School of Medicine in St. Louis, reported the ability to measure Aβ in the blood utilizing his Stable Isotope Label Kinetics (SILK) method. [Read more](#).
- » Gil Rabinovici, M.D., of the Memory and Aging Center, University of California, San Francisco, reported the interim results of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Study. Amyloid PET scans result in changes in medical management and reduced the need for additional diagnostic testing. [Read more](#).
- » The Alzheimer’s Association announces the launch of the \$20 million U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER). U.S. POINTER is a two-year clinical trial that will test the effectiveness of a multi-domain lifestyle intervention in preventing cognitive decline and dementia in 2,500 cognitively asymptomatic older adults (60-79 years old) who are at increased risk for cognitive decline due to health status, sedentary lifestyle and parental history of significant memory impairment. [Read more](#).
- » AABC members enjoyed scientific exchange and networking at the ISTAART Membership Reception and the Reviewers’ Reception.

Read additional press coverage of AAIC 2017 [here](#).

AABC Collaboration

Job postings

To submit job openings in future newsletters, please contact April Ross at aqross@alz.org.

General postings to the AABC membership

To submit any general information for future newsletters, please contact April Ross at aqross@alz.org.

To help us grow AABC, please continue to introduce new members and/or companies to our group. We also welcome ideas for this newsletter — or events — so we can better serve you. Please send your suggestions to April Ross at aqross@alz.org.